Modification of involuntary movements by centrally acting drugs.
D000625:Aminooxyacetic Acid / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D001971:Bromocriptine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology; D000882:Haplorhini; D007980:Levodopa / Q000037:antagonists & inhibitors; D009069:Movement Disorders / Q000139:chemically induced*; D010830:Physostigmine / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D010879:Piperazines; D010891:Piribedil / Q000037:antagonists & inhibitors; D011955:Receptors, Drug; D009435:Synaptic Transmission; D013787:Thalamic Nuclei / Q000502:physiology; D013806:Theophylline / Q000494:pharmacology
D000625:Aminooxyacetic Acid; D001285:Atropine; D001640:Bicuculline; D001971:Bromocriptine; D004298:Dopamine; D006220:Haloperidol; D007980:Levodopa; D010830:Physostigmine; D010852:Picrotoxin; D010879:Piperazines; D010891:Piribedil; D011955:Receptors, Drug; D013806:Theophylline